Electronic portal imaging device detection of radioopaque markers for the evaluation of prostate position during megavoltage irradiation: A clinical study

被引:200
作者
Vigneault, E
Pouliot, J
Laverdiere, J
Roy, J
Dorion, M
机构
[1] Ctr. Hosp. Univ. de Québec, Pavillon L'Hotel-Dieu de Quebec, Québec, Que.
[2] Radiation Oncology Department, CHUQ, Pavillon de L'Hotel-Dieu de Quebec, Québec, Que. G1R 2J6
来源
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS | 1997年 / 37卷 / 01期
关键词
radioopaque markers; prostate cancer; electronic portal imaging;
D O I
10.1016/S0360-3016(96)00341-0
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose: This study was designed to assess daily prostatic apex motion relative to pelvic bone structures during megavoltage irradiation. Methods and Materials: Radioopaque markers were implanted under ultrasound guidance near the prostatic apex of 11 patients with localized prostatic carcinoma, Patients were subsequently treated with a four field-box technique at a beam energy of 23 MV, During treatment, on-line images were obtained with an electronic portal imaging device (EPID), The marker was easily identified, even on unprocessed images, and the distance between the marker and a bony landmark was measured, Timelapse movies were also reviewed, After the completion of treatment, a transrectal ultrasound examination was performed in 8 of 11 patients, to verify the position of the marker. Results: We acquired over 900 digital portal images and analyzed posterioanterior and right lateral views, The quality of portal images obtained with megavoltage irradiation was good. It was possible to evaluate pelvic bone structures even without image histogram equalization, Moreover, the radioopaque marker was easily visible on every online portal image, The review of timelapse movies showed important interfraction motion of the marker while bone structures remained stable, We measured the position of the marker for each fraction, Marker displacements up to 1.6 cm were measured between 2 consecutive days of treatment, Important marker motions were predominantly in the posteroanterior and cephalocaudal directions. In eight patients, we verified the position of the marker relative to the prostatic apex with ultrasound at the end of the treatments, The marker remained in the trapezoid zone, Intratreatment images reviewed in two cases showed no change in marker position, Our results, obtained during the treatment courses, indicate similar or larger prostate motions than previously observed in studies that used intertreatment x-ray films and CT images, Marker implantation under transrectal ultrasound was well tolerated. Conclusions: Radioopaque marker and the use of electronic portal imaging give a direct evaluation of prostatic motion during radiation treatment, As suggested in previous studies the motions observed are predominantly in the posteroanterior and cephalocaudal directions. Therefore, prostate motion during treatment is important and must be considered especially when using conformal therapy. Copyright (C) 1997 by Elsevier Science Inc.
引用
收藏
页码:205 / 212
页数:8
相关论文
共 38 条
[1]  
ALI AHE, 1992, RADIOTHER ONCOL, V26, P162
[2]   THE RETROGRADE URETHROGRAM IS MORE ACCURATE THAN CT IN IDENTIFYING THE CAUDAL PROSTATE MARGIN FOR CONFORMAL TREATMENT PLANNING [J].
AMES, JW ;
HARTZ, W ;
LITWIN, S ;
HANKS, GE .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 1993, 27 :137-138
[3]  
Bagshaw M A, 1988, NCI Monogr, P47
[4]   MEASUREMENT OF PROSTATE MOVEMENT OVER THE COURSE OF ROUTINE RADIOTHERAPY USING IMPLANTED MARKERS [J].
BALTER, JM ;
SANDLER, HM ;
LAM, K ;
BREE, RL ;
LICHTER, AS ;
TENHAKEN, RK .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 1995, 31 (01) :113-118
[5]  
BALTER JM, 1994, 3 INT WORKSH EPID SE
[6]   ANALYSIS OF PROSTATE AND SEMINAL-VESICLE MOTION [J].
BEARD, CJ ;
BUSSIERE, MR ;
PLUNKETT, ME ;
COLEMAN, CN ;
KIJEWSKI, PK .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 1993, 27 :136-136
[7]   MAXIMIZING SETUP ACCURACY USING PORTAL IMAGES AS APPLIED TO A CONFORMAL BOOST TECHNIQUE FOR PROSTATIC-CANCER [J].
BIJHOLD, J ;
LEBESQUE, JV ;
HART, AAM ;
VIJLBRIEF, RE .
RADIOTHERAPY AND ONCOLOGY, 1992, 24 (04) :261-271
[8]   CANCER STATISTICS, 1994 [J].
BORING, CC ;
SQUIRES, TS ;
TONG, T ;
MONTGOMERY, S .
CA-A CANCER JOURNAL FOR CLINICIANS, 1994, 44 (01) :7-26
[9]  
CIONINI L, 1992, RAD ONCOL, V29, P230
[10]  
COX JA, 1993, INT J RADIAT ONCOL, V29, P299